A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
CompletedOBSERVATIONAL
Enrollment
64
Participants
Timeline
Start Date
May 1, 2016
Primary Completion Date
July 31, 2022
Study Completion Date
June 30, 2023
Conditions
Resectable Pancreatic Cancer
Interventions
DRUG
Nimotuzumab
Nimotuzumab (400mg) was given weekly
All Listed Sponsors
lead
Ruijin Hospital
OTHER
NCT06363084 - A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter